Advances in Twin-Screw Granulation Technologies

Published on: 


Friday, August 13, 2021 at 11am EDT| 8am PDT| 4pm BST|5pm CEST

Register Free:

Event Overview:

Granulation is a common process in pharmaceutical manufacturing to convert powder mixtures into agglomerated particles and is usually performed prior to tableting. Twin-screw granulation (TSG) has gained increased interest from the pharmaceutical industry for its potential within the development of oral dosage forms. It is a very flexible technology that can help to process a wide range of processed in a continuous manner. Twin-screw extruders offer excellent process control, can be equipped with high Process Analytical Tools (PAT), and processes can be optimized by using a Quality by Design (QbD) approach. All that leading to a high and stable product quality.

Within this webcast we review the basic concept of TSG, discuss the influence of process parameters on final product quality and give an insight into recent advances in TSG continuous manufacturing.

Key Learning Objectives:

  • Review the principles of TSG and granulation mechanisms
  • Understand continuous TSG systems, including state of the art systems
  • Learn about modeling of TSG
  • Understand quality-by-design approaches and process analytical technology for TSG

Who Should Attend:

Formulation scientists and engineers in the pharmaceutical industry Academics who want to learn more about the possibilities to use TSG for wet and melt granulation in R&D and manufacturing.


Dennis Douroumis
Professor in Pharmaceutical Technology and Process Engineering;
Director of Centre for Innovation in Process Engineering and Research

Professor Dennis Douroumis obtained a bachelor’s degree in chemistry and doctorate from the department of pharmacy at Patras University in Greece. He worked as a postdoctoral fellow (2004) at the Friedrich–Schiller University of Jena, Department of Pharmacy for the development of parenteral formulations of anti-epileptic drugs (Novartis Pharma, Basel). He also worked as a team leader (2005) in the development of nano-liposomal formulations and treatment of rheumatoid arthritis by applying photodynamic therapy (Biolitec Pharma GmbH.) Following this, he worked for Phoqus Pharmaceutical plc as a senior scientist at the product development department.

His research area focuses on the development of secondary continuous manufacturing by using hot-melt extrusion (HME) of extrusion granulation coupled with process analytical technology tools. His group is also involved in development of targeted anti-cancer drug delivery systems such as SLNs or NLCs produced by high-pressure homogenization. He is actively involved in ink-jetting and 3D-printing technologies for the development of medical devices (e.g. microneedles, stents) and personalized medicines.

Dr. Douroumis has published more than 80 research articles and seven book chapters, and edited two books on HME and the delivery of water-insoluble APIs. He has patented two proprietary technologies on the coating of transdermal microneedles and printing of drug eluting stents. Professor Douroumis has delivered keynote presentations at national and international conferences while his group has presented several poster presentations.

Register Free: